Figure 8
From: Inflammation drives pathogenesis of early intestinal failure-associated liver disease
Potential therapeutics identified as strongly inhibited upstream regulators in Ingenuity Pathway Analysis. Methylprednisolone succinate is predicted to directly counteract multiple upregulated inflammatory regulators including NF-kB, STAT2, IRF9, and JUN via NR3C1 (a). Simvastatin is predicted to indirectly inhibit multiple inflammatory regulators including NF-kB, STAT1, STAT3, Smad, and JUN (b). Darker color demonstrates greater magnitude of pathway activation or inhibition.
